Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.

The RANK-RANKL-OPG system is an essential signaling pathway involved in bone cell-cell communication, with ample evidence that modification of the RANK-RANKL-OPG signaling pathway has major effects on bone remodeling. The first focus of this paper is to demonstrate that a theoretical model of bone cell-cell interactions is capable of qualitatively reproducing changes in bone associated with RANK-RANKL-OPG signaling. To do this we consider either biological experiments or bone diseases related to receptor and/or ligand deficiencies, including RANKL over-expression, ablation of OPG production and/or RANK receptor modifications. The second focus is to investigate a wide range of possible therapeutic strategies for re-establishing bone homeostasis for various pathologies of the RANK-RANKL-OPG pathway. These simulations indicate that bone diseases associated with the RANK-RANKL-OPG pathway are very effective in triggering bone resorption compared to bone formation. These results align with Hofbauer's "convergence hypothesis", which states that catabolic bone diseases most effectively act through the RANK-RANKL-OPG system. Additionally, we demonstrate that severity of catabolic bone diseases strongly depends on how many components of this pathway are affected. Using optimization algorithms and the theoretical model, we identify a variety of successful "virtual therapies" for different disease states using both single and dual therapies.

[1]  L. Hofbauer,et al.  The OPG/RANKL/RANK system in metabolic bone diseases. , 2004, Journal of musculoskeletal & neuronal interactions.

[2]  Peter Pivonka,et al.  Model structure and control of bone remodeling: a theoretical study. , 2008, Bone.

[3]  H. Yamazaki,et al.  Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. , 2005, Journal of electron microscopy.

[4]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[5]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[6]  Nadine A Defranoux,et al.  In Silico Modeling and Simulation of Bone Biology: A Proposal , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  G. Rodan,et al.  Role of osteoblasts in hormonal control of bone resorption—A hypothesis , 2006, Calcified Tissue International.

[8]  N. Bell RANK ligand and the regulation of skeletal remodeling. , 2003, The Journal of clinical investigation.

[9]  L. Hofbauer,et al.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.

[10]  L. Xing,et al.  Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  L. Xing,et al.  Functions of RANKL/RANK/OPG in bone modeling and remodeling. , 2008, Archives of biochemistry and biophysics.

[12]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[13]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[14]  Svetlana V Komarova,et al.  Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. , 2003, Bone.

[15]  Vincent Lemaire,et al.  Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.

[16]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  N. Maalouf,et al.  CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  A. Parfitt Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. , 2002, Bone.

[19]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Martin Tj Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004 .

[21]  B. L. Riggs,et al.  Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  J. Aubin,et al.  Advances in the osteoblast lineage. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[24]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.